Research Analysts Offer Predictions for ANRO FY2025 Earnings

Alto Neuroscience, Inc. (NYSE:ANRO) – Equities researchers at Wedbush lifted their FY2025 earnings per share (EPS) estimates for shares of Alto Neuroscience in a research report issued to clients and investors on Tuesday, October 21st. Wedbush analyst L. Chico now expects that the company will earn ($2.40) per share for the year, up from their prior forecast of ($2.59). The consensus estimate for Alto Neuroscience’s current full-year earnings is ($2.54) per share. Wedbush also issued estimates for Alto Neuroscience’s Q4 2025 earnings at ($0.54) EPS, Q1 2026 earnings at ($0.43) EPS, Q2 2026 earnings at ($0.44) EPS, Q3 2026 earnings at ($0.46) EPS, Q4 2026 earnings at ($0.47) EPS, FY2026 earnings at ($1.80) EPS, FY2027 earnings at ($1.97) EPS, FY2028 earnings at ($2.27) EPS and FY2029 earnings at ($2.23) EPS.

Alto Neuroscience (NYSE:ANRO) last announced its earnings results on Wednesday, August 13th. The company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.08).

A number of other research firms have also weighed in on ANRO. Chardan Capital initiated coverage on Alto Neuroscience in a research report on Monday, September 29th. They set a “buy” rating and a $15.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Alto Neuroscience in a report on Wednesday, October 8th. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Alto Neuroscience in a report on Monday, August 18th. Finally, Robert W. Baird raised their price objective on shares of Alto Neuroscience from $10.00 to $16.00 and gave the company an “outperform” rating in a research note on Monday. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Alto Neuroscience has a consensus rating of “Moderate Buy” and a consensus target price of $11.00.

Alto Neuroscience Stock Down 5.9%

Shares of Alto Neuroscience stock opened at $10.22 on Thursday. The company has a debt-to-equity ratio of 0.18, a current ratio of 18.43 and a quick ratio of 18.43. The company has a 50-day moving average of $4.72 and a 200 day moving average of $3.29. The firm has a market cap of $276.62 million, a price-to-earnings ratio of -4.27 and a beta of 2.00. Alto Neuroscience has a 1 year low of $1.60 and a 1 year high of $12.19.

Institutional Investors Weigh In On Alto Neuroscience

A number of institutional investors and hedge funds have recently modified their holdings of ANRO. SCS Capital Management LLC bought a new stake in Alto Neuroscience during the 1st quarter valued at $144,000. Nuveen LLC purchased a new position in shares of Alto Neuroscience during the first quarter valued at $302,000. AWM Investment Company Inc. increased its position in Alto Neuroscience by 31.1% during the 1st quarter. AWM Investment Company Inc. now owns 901,984 shares of the company’s stock valued at $1,948,000 after purchasing an additional 214,153 shares during the period. Citizens Financial Group Inc. RI purchased a new position in Alto Neuroscience during the 1st quarter valued at about $83,000. Finally, Armistice Capital LLC increased its position in Alto Neuroscience by 146.2% during the 1st quarter. Armistice Capital LLC now owns 1,600,000 shares of the company’s stock valued at $3,456,000 after purchasing an additional 950,000 shares during the period.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.